Crinetics stock price target raised to $85 from $65 at Jones Trading

Crinetics Pharmaceuticals (CRNX) has secured FDA approval for Palsonify, its daily oral treatment for acromegaly, prompting significant analyst upgrades and increased price targets, including Jones Trading raising its target to $85 and JMP Securities to $143. The company has set a high wholesale acquisition cost (WAC) of $290,000 annually, substantially above current injectable treatments, which analysts project will drive significant revenue, with Jones Trading forecasting $1.2 billion in worldwide sales by 2032. This approval and aggressive pricing strategy are viewed as transformative for Crinetics' outlook, despite expectations of potentially slow initial market penetration.

Analysis

Crinetics Pharmaceuticals (CRNX) has secured a significant catalyst with the FDA's approval of its daily oral acromegaly treatment, Palsonify. The approval has de-risked the company's outlook, evidenced by a broad consensus of positive analyst rating reiterations and substantial price target increases, including a move to $85 from Jones Trading and a notable jump to $143 from JMP Securities. A key element of the investment thesis is the aggressive pricing strategy, with a wholesale acquisition cost (WAC) set at $290,000 annually, positioning it at a premium to the standard-of-care injectable treatments which range from $72,000 to $240,000 per year. This pricing underpins projections such as Jones Trading's forecast for $1.2 billion in worldwide sales by 2032. However, a degree of near-term caution is warranted, as the company anticipates a slow initial market uptake due to the annual cadence of endocrinologist visits for most patients. Analysts have factored this in by adjusting initial launch metrics, while simultaneously increasing the drug's probability of success to 100% in their models. The long-term valuation is further supported by the potential application of Palsonify in carcinoid syndrome, with a Phase 3 trial anticipated in the second half of 2026, for which analysts are already incorporating the high WAC.

Key Decisions for Investors

• Given the FDA approval and robust analyst price targets, investors may view Crinetics as a de-risked growth opportunity, with the $290,000 annual price for Palsonify providing a clear pathway to significant long-term revenue.
• Investors should closely monitor the initial commercial launch and sales ramp-up, as management's guidance for a slow initial uptake could lead to near-term volatility if early revenue figures fall short of elevated market expectations.
• Consider the additional pipeline value from the potential carcinoid syndrome indication, which is already being factored into valuation models and could provide further upside beyond the initial acromegaly market.